Exclusion criteria were previous cancer of any pelvic organ, systemic glucocorticoid treatment, insulin-treated diabetes, an inability to participate in study follow-up or even to provide knowledgeable consent, or the need for concomitant surgical treatment. Oral and written informed consent was acquired from all participants. The trial was conducted relative to the protocol .10 The study was approved by the appropriate research ethics committees in each country.Namal Nawana, Interim CEO and Chief Operating Officer of Alere said, ‘The second quarter was an interval of significant changeover for Alere. With the lately announced alter in leadership, we are actually narrowing our focus on our global leading speedy diagnostic business and seeking opportunities with the highest potential for value creation. This new strategic direction will center on Alere's core strengths in quick diagnostics and our focus areas of infectious and cardiometabolic toxicology and disease, that may enhance our capability to deliver more improved and consistent financial results. Alere's Board and management team are committed to determining the best allocation of assets to drive growth and shareholder value creation.’ Financial outcomes for the second quarter of 2014: Net revenue of $737.9 million for the second quarter of 2014, compared to $764.0 million for the next quarter of 2013.